Clinical Laboratory Tests Market – By Test Type, By End Use - Global Forecast 2025 – 2034

Clinical Laboratory Tests Market Size

The global clinical laboratory tests market size was valued at around USD 125.5 billion in 2024 and is estimated to grow at 9.1% CAGR from 2025 to 2034. Clinical laboratory tests are medical assays performed on blood, urine, or tissues to identify, track, or screen for various health complications. These tests utilize diagnostic tools which include test kits, reagents, clinical analyzers, specimen collection devices, and other consumable materials. They are a prerequisite for medical decision making as determined by the evidence in clinical care settings.
 

The prevalence of chronic diseases has been growing globally, which is a factor primarily impacting the growth of clinical laboratory tests positively. For instance, according to the World Health Organization (WHO), approximately 74% of deaths occurring globally are due to noncommunicable diseases (NCDs), along with 17 million premature deaths every year.
 

 Moreover by 2050, if the current trends were to continue, chronic conditions such as cancer, diabetes, cardiovascular diseases, and respiratory diseases would account for 86% of the 90 million annual deaths, which is 90% of increase in absolute numbers since 2019. These statistics highlight the need for robust diagnostic capabilities, especially in the underdeveloped and developing economies that lack resources. This issue is alleviated by clinical laboratory tests, which offer cost-effective, scalable, and accessible diagnostic solutions.
 

In addition, the global increase in the elderly population is one of the key reasons behind the expanding market of clinical laboratory tests, as older adults tend to need more diagnostic assessments as part of their health evaluations due to aging issues. The elderly are more susceptible to chronic conditions such as cardiovascular diseases, diabetes, kidney failure, and multiple forms of cancer, all of which require periodic laboratory testing for effective disease control. According to the data of the United Nations, the world population aged 65 and over is forecasted to increase from 761 million in 2021 to 1.6 billion by 2050. This shift in demography will continue to strain the healthcare systems which will require an increased diagnostic and age-appropriate testing capabilities. Thus, in response to this challenge, clinical laboratories are upgrading the infrastructure and adopting new changes to automate test procedures and incorporating other forms of non-invasive testing to fulfill the diagnostic requirements of this older population, which is expected to enhance sustained market growth.
 

Clinical Laboratory Tests Market Trends

• The adoption of new technologies such as molecular diagnostics is easing the detection of numerous diseases due to their specificity and sensitivity. For example, QIAGEN’s QIAstat-Dx and NeuMoDx systems provide rapid infectious disease and oncology markers multiplex molecular testing which enables precise diagnostic and improves clinical turnaround time.
   
• Further, application of AI and laboratory automation are now active features in laboratory workflows. This allows for improvement in diagnostic accuracy and efficiency.
   
• Moreover, the introduction of point-of-care testing (POC) devices and their increasing popularity is leading to the rerouting of some routine diagnostics, away from centralized labs. For instance, the Abbott i-STAT system allows for rapid blood testing, the market for which is expected to reach USD 142.2 billion by 2032, at the site for cardiac markers and electrolytes, which increases emergency services and triaging of patients.
   
• Additionally, the rising need for panels and multiplex assays contributed to the increase in multi-analyte testing. Allergy diagnosis is now more efficient and cost-effective with the issuing of the Thermo Fisher Scientific ImmunoCAP ISAC microarray which permits simultaneous IgE testing for over 100 allergens in a single test run.
   
• Furthermore, stricter regulations and quality standards are affecting innovation and validation of products. For example, in 2022, the EU In Vitro Diagnostic Regulation (IVDR) sharply increased performance and clinical evidence requirements for diagnostics, fundamentally changing the approval process within the EU by replacing the In Vitro Diagnostic Directive (IVDD), which preceded it, significantly enhancing emphasis on ancillary accuracy and traceability.
   

Trump Administration Tariffs

• Manufacturers in the clinical laboratory test industry are likely to incur additional costs owing to the Trump administration’s tariffs on foreign medical-grade components and materials.
   
• These tariffs could affect critical inputs such as reagent-grade chemicals, diagnostic antibodies, lab plastics such as pipette tips and microtiter plates, as well as electronic modules required for analyzer systems. As a large constituency of these materials is sourced from China, businesses may suffer from squeezed margins and interrupted production.
   
• In an effort to solve these issues, some manufacturers may evaluate their global procurement policies and shift sourcing strategies towards India, South Korea, or Eastern Europe which provide GMP-compliant manufacturing infrastructure without any exposure to trade conflicts. This change would be most important for IVD manufacturers who rely heavily on low-cost input from overseas.
   
• More specifically, clinical laboratories and healthcare providers might experience restricted availability, longer waiting times, or price increases for specific test kits and instruments. In turn, companies might focus on supplier diversification, enhancing regional supply chains, and domestic parts manufacturing.
   

Clinical Laboratory Tests Market Analysis

Based on test type, the market is segmented into complete blood count, HbA1c, metabolic panel, liver panel, renal panel, lipid panel, cardiovascular panel, other test types. The global market was valued at USD 125.5 billion in 2024. The HbA1c segment dominated the market with the largest revenue share of 13.9% in 2024.
 

• This dominance is primarily attributed to the increasing global cases of diabetes, which requires the periodic HbA1c testing (glycated hemoglobin) for both the diabetic patient's initial assessment and for long-term monitoring of glycemic control. As per the International Diabetes Federation, there were around 537 million adults with diabetes in 2021, and it is projected to rise to 643 million by 2030. Primary care physicians are now using HbA1c tests as the first-line diabetes test because these tests can provide information about the patient’s average blood glucose levels over the prior 2 to 3 months.
   
• The segment has also gained from the recent development in assay technologies, such as point-of-care HbA1c analyzers and automated high-throughput systems, which improve operational and diagnostic efficiency.
   
• Moreover, heightened awareness, along with screening drives in the developed and developing regions has surged the volume of the tests performed. HbA1c testing is offered as part of the routine health checkup in several countries globally. This strengthens its use as the most required clinical laboratory test, driving the revenue growth in the segment.
  
   

Based on end use, the clinical laboratory tests market is segmented into central laboratories, primary clinics, hospitals, and other end users. Central laboratories segment dominated the market with the largest revenue share of USD 47.2% in 2024.
 

• This dominance is due to presence of advanced infrastructure across central laboratories, automated high throughput systems, and integration with extensive healthcare networks which facilitate high volume throughput.
   
• Central labs are preferred for complex diagnostic panels including genetic, molecular, and other multi-analyte tests because they have necessary resources required for these sophisticated tests, as well as the expert manpower needed to conduct them.
   
• Besides, central laboratories have the strongest market position owing to their uniform dependable test results and economical testing solutions. Strategic partnerships with hospitals and clinical research organizations further extend their coverage and enhance their diagnostic capabilities, driving the revenue growth in the segment.

North America: The U.S. clinical laboratory tests market is projected to grow significantly, from USD 50.8 billion in 2024 to USD 119.3 billion by 2034.
 

• The U.S. had the most demanding market for the clinical laboratory tests owing to its demographic structure, disease burden, and healthcare system. As per the World Bank Group, the U.S spends USD 1,232 on health per capita, which is the highest in the world, and enables the use of modern diagnostic and laboratory technologies.
   
• According to the U.S. Census Bureau, people aged 65 and older are projected to grow from 58 million in 2022 to 82 million by 2050, an increase of 47%. This shift is anticipated to greatly increase the requirement of diagnostic solutions for proper treatment and disease management.
   
• Furthermore, U.S.-based companies such as Thermo Fisher Scientific, Danaher, and Abbott Laboratories are among the global leaders in next-generation sequencing (NGS), molecular diagnostics, and automation platforms, which contributes to the growth of market in the U.S.
   

Europe: The clinical laboratory tests market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The country has been facing a surge in its aging population. According to the Office for National Statistics (ONS), it is expected that by 2050, 1 in 4 people in the UK will be aged 65 or above.
   
• With this increase in population, the country is witnessing an increasing burden of chronic conditions, such as Diabetes, which is a significant factor responsible for the growth of clinical laboratory tests in the UK.
   
• According to the data provided by Diabetes UK, there are currently over 5.8 million diabetes sufferers in the country. Approximately 1.3 million such people are estimated to be undiagnosed with type 2 diabetes, further fostering the market.
   
• In addition, the National Health Service (NHS) in UK allows for universal access to diagnostic testing, which ensures a persistently high volume of tests conducted throughout the country. The NHS also funds screening programs for some cancers, STIs, and certain metabolic diseases which supports clinical laboratory needs.
   

Asia Pacific: Japan clinical laboratory tests market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan's universal health insurance system ensures that every individual can economically access diagnostic services. This leads to a high baseline utilization rate for laboratory services. Policies at the government level foster preventive checkups along with regular health screenings, thus promoting clinical laboratory tests throughout the country.
   
• In addition, Japan's aging population is a major factor driving demand for clinical laboratory tests. According to Statista, 36.35 million people (29% of the population) were aged 65 or older, as of November 2023. Older people are more prone to diabetes and various other diseases thus further fostering the expansion of this market in Japan.
   
• The Japanese government has national screening programs (such as Population-Based Cancer Screening Programs) for major types of cancers, lifestyle diseases, infectious diseases and puts great emphasis on early detection. Japan is one of the countries that focuses on investing in genomic medicine and personalized healthcare, which is propelling the use of advanced diagnostics technology, further driving the market growth.
   

Middle East and Africa: The clinical laboratory tests market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• In Saudi Arabia, the demand for clinical laboratory tests is on the rise. This demand has increased because of demographic and epidemiological factors. The aging population is rising rapidly, with those 60 years or older increasing 5-fold from 2 million in the year 2020 i.e., 5.9% of the total population of the country to 10.5 million by 2050.
   
• Additionally, the rising burden of chronic diseases such as diabetes also supports the necessity for effective diagnostics, thus increasing the market growth. The Saudi Diabetes Federation states that in 2021, there were alarming 4.3 million reported cases of diabetes among adult population of the country.
   
• Further, Saudi Arabia is heavily investing in the healthcare infrastructure, such as diagnostic labs and medical facilities, under its Vision 2030 initiative aimed at modernizing the country. Government support towards public-private partnerships is enhancing the construction of specific automated and specialized laboratory facilities, which is further aiding to the market growth.
   

Clinical Laboratory Tests Market Share

The market is characterized by a moderate degree of fragmentation, featuring a combination of multinational IVD firms and local diagnostic equipment companies. Top 4 companies such as Siemens Healthineers, Abbott Laboratories, F. Hoffman La Roche, and Beckman Coulter held cumulatively about 40% of the market share. These firms lead in essential product lines comprising chemistry analyzers, immunoassay systems, and automated hematology systems.
 

There is a growing focus among market players toward next-generation diagnostic systems that incorporate molecular testing and AI algorithms. Strategic collaborations with clinical research organizations and software companies are enhancing the speed and automated precision of testing and diagnostics, particularly for oncology, cardiometabolic, and infectious disease panels.
 

Clinical Laboratory Tests Market Companies

Some of the eminent market participants operating in the clinical laboratory tests industry include:

• Abbott Laboratories
• Agilent Technologies
• Becton, Dickinson and Company
• bioMérieux
• Bio-Rad Laboratories
• Danaher
• F. Hoffmann-La Roche
• Grifols
• Hologic
• Illumina
• PerkinElmer
• QIAGEN
• QuidelOrtho
• Siemens Healthineers
• Thermo Fisher Scientific
   
• Abbott Laboratories has a wide portfolio of clinical chemistry and immunoassay analyzers provided under ARCHITECT and Alinity platforms. Further, the company has scaled its R&D earmarked for oncology, cardiology, and infectious disease testing serving as a basis for further growth. The company’s global footprint and vertically integrated operations provide scalability and rapid deployment across lab facilities.
   
• F. Hoffmann-La Roche is well known in the industry of molecular diagnostics and clinical chemistry, enhanced by Cobas series systems. The company focuses on diagnostics as well as outcome monitoring and integrates health digital solutions with the laboratory, improving workflow efficiency. A strong pipeline of tests based on proprietary biomarker discovery and clinical collaboration actively supports the company.
   
• Siemens Healthineers has a strong and differentiated position within the clinical laboratory testing market due to its integrated technology infrastructure and worldwide presence. The company provides complete portfolios of laboratory testing solutions which comprise immunoassay, clinical chemistry, hematology, coagulation, and molecular diagnostics, across unified platform such as Atellica Solution.
   

Clinical Laboratory Tests Industry News:

• In March 2025, Beckman Coulter (a subsidiary of Danaher) announced U.S. FDA approval of its DxC 500i Clinical Analyzer, which is an integrated clinical chemistry and immunoassay analyzer. The DxC 500i has cutting-edge technology incorporated into it along with an easy navigational system so that all forms of medical labs are capable of attending to the needs of modern medical care.
   
• In February 2025, bioMérieux announced that it has received clearance from U.S. FDA for the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid, which is a midplex molecular panel identifying 11 common pathogens associated with a disease - gastroenteritis. These include viruses, bacteria, and parasites. Results are delivered in 1 hour from a single sample, supporting for quicker diagnoses of gastrointestinal infections.
   
• In January 2025, Beckman Coulter (a subsidiary of Danaher) announced to receive U.S. FDA “Breakthrough Device” designation for its Access p?Tau217/β-Amyloid 1-42 plasma ratio. This blood test helps health care professionals locate those patients which have amyloid pathology connected to Alzheimer’s disease.
   
• In May 2024, QIAGEN announced U.S. FDA approval for its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat-Dx Respiratory Panel Plus helps in the clinical diagnosis of upper respiratory tract infections and has a coverage of 21 viruses and bacteria.
   

The clinical laboratory tests market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Complete blood count
• HbA1c
• Metabolic panel
• Liver panel
• Renal panel
• Lipid panel
• Cardiovascular panel
• Other test types

Market, By End Use

• Central laboratories
• Primary clinics
• Hospitals
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE